

1. A compound of Formula I:



R<sup>1</sup> is C<sub>1</sub>-C<sub>2</sub> alkyl or C<sub>1</sub>-C<sub>2</sub> fluoroalkyl;


R<sup>3</sup> is 4- to 8-membered heterocyclyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (4- to 8-membered heterocyclyl)-C<sub>1</sub>-C<sub>4</sub> alkyl-, or (C<sub>3</sub>-C<sub>8</sub> cycloalkyl)-C<sub>1</sub>-C<sub>4</sub> alkyl-,

wherein each of the 4- to 8-membered heterocyclyl and the 4- to 8-membered heterocyclyl moiety in (4- to 8-membered heterocyclyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- is optionally substituted with 1 or 2 R<sup>5</sup>,

wherein each of the C<sub>3</sub>-C<sub>8</sub> cycloalkyl and the C<sub>3</sub>-C<sub>8</sub> cycloalkyl moiety in (C<sub>3</sub>-C<sub>8</sub> cycloalkyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- is optionally substituted with 1 or 2 R<sup>5</sup> and further optionally substituted with 1 -N(R<sup>6</sup>)<sub>2</sub>, and

wherein each of the C<sub>1</sub>-C<sub>4</sub> alkyl moieties in (4- to 8-membered heterocyclyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- and (C<sub>3</sub>-C<sub>8</sub> cycloalkyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- is optionally substituted with 1, 2, or 3 R<sup>5</sup>;

R<sup>4</sup> is a moiety having the structure of



fluoroalkoxy-C<sub>1</sub>-C<sub>4</sub> alkyl-, C<sub>1</sub>-C<sub>4</sub> alkoxy-C<sub>1</sub>-C<sub>4</sub> fluoroalkyl, and C<sub>1</sub>-C<sub>4</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>4</sub> fluoroalkyl-;

each R<sup>6</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>2</sub> alkyl;

each R<sup>7</sup> is independently H or C<sub>1</sub>-C<sub>2</sub> alkyl; and

each R<sup>8</sup> is independently H, F, or C<sub>1</sub>-C<sub>2</sub> alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

A is CH or N;

R<sup>1</sup> is CH<sub>3</sub> or C<sub>1</sub> fluoroalkyl;

R<sup>2</sup> is CH<sub>3</sub>;

R<sup>3</sup> is 5- to 7-membered heterocyclyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl,


(5- to 7-membered heterocyclyl)-C<sub>1</sub>-C<sub>4</sub> alkyl-, or (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)-C<sub>1</sub>-C<sub>4</sub> alkyl-,

wherein each of the 5- to 7-membered heterocyclyl and the 5- to 7-membered heterocyclyl moiety in (5- to 7-membered heterocyclyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- is optionally substituted with 1 R<sup>5</sup>,

wherein each of the C<sub>3</sub>-C<sub>6</sub> cycloalkyl and the C<sub>3</sub>-C<sub>6</sub> cycloalkyl moiety in (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- is optionally substituted with 1 or 2 R<sup>5</sup> and further optionally substituted with 1 -N(R<sup>6</sup>)<sub>2</sub>, and

wherein each of the C<sub>1</sub>-C<sub>4</sub> alkyl moieties in (5- to 7-membered heterocyclyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- and (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)-C<sub>1</sub>-C<sub>4</sub> alkyl- is optionally substituted with 1, 2, or 3 R<sup>5</sup>;

R<sup>4</sup> is a moiety having the structure of




each R<sup>5</sup> is independently selected from the group consisting of -F, -OH, -CN, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-;

each R<sup>6</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>2</sub> alkyl; and

each R<sup>7</sup> is independently H or CH<sub>3</sub>, provided that no more than two R<sup>7</sup> are CH<sub>3</sub>.

3. The compound of claim 1 or 2, wherein the compound is a compound of Formula II:




II

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein the two substituents on the tetrahydropyran ring of Formula II are *trans* to each other.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula III:




III.

6. The compound of claim 3 or 4, or a pharmaceutically acceptable salt thereof, wherein:  
A is CH or N;  
R<sup>3</sup> is 5- to 7-membered heterocyclyl optionally substituted with 1 R<sup>5</sup>; and

R<sup>5</sup> is selected from the group consisting of F, OH, -CN, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula III:



III.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is selected from the group consisting of 2-azaspiro[3.3]heptanyl, tetrahydrofuranyl, pyrrolidinyl, and piperidinyl, wherein each of the heterocyclyl selections is optionally substituted with 1 R<sup>5</sup>; and R<sup>5</sup> is selected from the group consisting of F, OH, -CN, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-.


9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is 2-azaspiro[3.3]heptan-6-yl optionally substituted with 1 R<sup>5</sup> that is selected from the group consisting of C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-.

10. The compound of claim 3 or 4, or a pharmaceutically acceptable salt thereof, wherein:  
A is CH or N;  
R<sup>3</sup> is C<sub>3</sub>-C<sub>6</sub> cycloalkyl optionally substituted with 1 or 2 R<sup>5</sup> and further optionally substituted with 1 -N(R<sup>6</sup>)<sub>2</sub>;

each R<sup>5</sup> is independently selected from the group consisting of F, OH, -CN, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-; and

each R<sup>6</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>2</sub> alkyl.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula III:



III.

12. The compound of any one of claims 1 to 5, 10, and 11, or a pharmaceutically acceptable salt thereof, wherein:

A is CH or N;

R<sup>3</sup> is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and bicyclo[3.1.0]hexanyl, wherein each of the selections is optionally substituted with 1 or 2 R<sup>5</sup>, and further optionally substituted with 1 -N(R<sup>6</sup>)<sub>2</sub>;

each R<sup>5</sup> is independently selected from the group consisting of F, OH, -CN, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-; and

each R<sup>6</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>2</sub> alkyl.

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and

bicyclo[3.1.0]hexanyl, wherein each of the selections is optionally substituted with 1 or 2 R<sup>5</sup> and further optionally substituted with 1 -N(R<sup>6</sup>)<sub>2</sub>.

14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and bicyclo[3.1.0]hexan-2-yl, wherein each of the cycloalkyl selections is optionally substituted with 1 or 2 R<sup>5</sup> and further optionally substituted with 1 -N(R<sup>6</sup>)<sub>2</sub>.

15. The compound of any one of claims 12, 13, and 14, or a pharmaceutically acceptable salt thereof, wherein each R<sup>5</sup> is independently selected from the group consisting of F, OH, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, and C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-.

16. The compound of any one of claims 12, 13, and 14, or a pharmaceutically acceptable salt thereof, wherein each R<sup>5</sup> is independently selected from the group consisting of F, OH, CH<sub>3</sub>, and CH<sub>2</sub>CH<sub>3</sub>; and each R<sup>6</sup> is independently selected from the group consisting of H and CH<sub>3</sub>.

17. The compound of any one of claims 12 to 16, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is cyclobutyl optionally substituted with 1 or 2 R<sup>5</sup>.

18. The compound of any one of claims 10 to 14, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is cyclobutyl optionally substituted with 1 or 2 R<sup>5</sup>; and each R<sup>5</sup> is independently selected from the group consisting of F, OH, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-.

19. The compound of any one of claims 10 to 16, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is cyclopentyl optionally substituted with 1 or 2 R<sup>5</sup>.

20. The compound of any one of claims 10 to 14, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is cyclopentyl optionally substituted with 1 or 2 R<sup>5</sup>; and each R<sup>5</sup> is independently selected from the group consisting of F, OH, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> alkyl-, C<sub>1</sub>-C<sub>2</sub> alkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl, and C<sub>1</sub>-C<sub>2</sub> fluoroalkoxy-C<sub>1</sub>-C<sub>2</sub> fluoroalkyl-.

21. The compound of any one of claims 10 to 16, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> is cyclopentyl.

22. The compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein A is CH.

23. The compound of any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein A is N.

24. ~~A-~~The compound of claim 1, wherein the compound is selected from:

6-acetyl-8-cyclobutyl-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-acetyl-8-cyclopentyl-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-acetyl-8-(2-azaspiro[3.3]heptan-6-yl)-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-acetyl-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methyl-8-[(1*R*,2*S*)-2-methylcyclopentyl]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

3-acetyl-1-cyclopentyl-7-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-4-methyl-1,6-naphthyridin-2(1*H*)-one;

6-acetyl-8-[(1*S*,2*R*,5*R*)-bicyclo[3.1.0]hexan-2-yl]-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-acetyl-8-[(1*R*,2*S*,5*S*)-bicyclo[3.1.0]hexan-2-yl]-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-acetyl-8-[(1*R*,2*S*)-2-fluoro-2-methylcyclopentyl]-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one;

6-acetyl-8-[(1*S*,2*R*)-2-fluoro-2-methylcyclopentyl]-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one; and

6-acetyl-8-[2-(2,2-difluoroethyl)-2-azaspiro[3.3]heptan-6-yl]-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one,  
or a pharmaceutically acceptable salt thereof.

25. A compound that is 6-acetyl-8-cyclobutyl-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one, or a pharmaceutically acceptable salt thereof.
26. A compound that is 6-acetyl-8-cyclopentyl-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one, or a pharmaceutically acceptable salt thereof.
27. A compound that is 6-acetyl-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methyl-8-[[*(1R,2S)*-2-methylcyclopentyl]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one, or a pharmaceutically acceptable salt thereof.
28. A compound that is 3-acetyl-1-cyclopentyl-7-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-4-methyl-1,6-naphthyridin-2(1*H*)-one, or a pharmaceutically acceptable salt thereof.
29. A compound that is 6-acetyl-8-[2-(2,2-difluoroethyl)-2-azaspiro[3.3]heptan-6-yl]-2-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-5-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one, or a pharmaceutically acceptable salt thereof.
30. A crystalline form of 3-acetyl-1-cyclopentyl-7-[[*(3S,4R)*-3-hydroxytetrahydro-2*H*-pyran-4-yl]amino]-4-methyl-1,6-naphthyridin-2(1*H*)-one.
31. The crystalline form of claim 30, wherein the crystalline form is anhydrous.
32. The crystalline form of claim 31, wherein the crystalline form (~~designated as Form I~~) has a powder X-ray diffraction pattern (CuK $\alpha$  radiation) comprising at least two characteristic peaks, in terms of  $2\theta$ , selected from at  $8.0 \pm 0.2^\circ$ ;  $18.6 \pm 0.2^\circ$ ;  $19.1 \pm 0.2^\circ$ ; and  $21.3 \pm 0.2^\circ$ .
33. The crystalline form of claim 32, having a powder X-ray diffraction pattern (CuK $\alpha$  radiation) comprising at least three characteristic peaks, in terms of  $2\theta$ , selected from at  $8.0 \pm 0.2^\circ$ ;  $18.6 \pm 0.2^\circ$ ;  $19.1 \pm 0.2^\circ$ ; and  $21.3 \pm 0.2^\circ$ .

34. The crystalline form of claim 32 or 33, having a powder X-ray diffraction pattern (CuK $\alpha$  radiation) comprising four characteristic peaks, in terms of  $2\theta$ , ~~selected from~~ at  $8.0 \pm 0.2^\circ$ ;  $18.6 \pm 0.2^\circ$ ;  $19.1 \pm 0.2^\circ$ ; and  $21.3 \pm 0.2^\circ$ .

35. The crystalline form of any one of claims 32 to 34, having a powder X-ray diffraction pattern (CuK $\alpha$  radiation) further comprising at least one additional characteristic peak, in terms of  $2\theta$ , ~~as those listed in Table X1~~ selected from at  $14.9 \pm 0.2^\circ$ ;  $16.0 \pm 0.2^\circ$ ;  $16.2 \pm 0.2^\circ$ ;  $17.4 \pm 0.2^\circ$ ;  $19.9 \pm 0.2^\circ$ ;  $20.8 \pm 0.2^\circ$ ;  $20.9 \pm 0.2^\circ$ ;  $21.5 \pm 0.2^\circ$ ;  $21.8 \pm 0.2^\circ$ ;  $22.3 \pm 0.2^\circ$ ;  $23.3 \pm 0.2^\circ$ ;  $26.0 \pm 0.2^\circ$ ;  $26.2 \pm 0.2^\circ$ ;  $26.5 \pm 0.2^\circ$ ;  $28.1 \pm 0.2^\circ$ ;  $30.0 \pm 0.2^\circ$ ;  $30.4 \pm 0.2^\circ$ ;  $31.1 \pm 0.2^\circ$ ;  $32.3 \pm 0.2^\circ$ ;  $33.2 \pm 0.2^\circ$ ;  $33.9 \pm 0.2^\circ$ ; and  $36.2 \pm 0.2^\circ$ .

~~36. The crystalline form of any one of claims 32 to 35 having a powder X-ray diffraction pattern substantially as shown in Figure 1.~~

~~37~~36. A pharmaceutical composition comprising a compound of any one of claims 1 to 29<sub>1</sub> or a pharmaceutically acceptable salt thereof<sub>1</sub> or ~~the~~ a crystalline form of any one of claims 30 to ~~36~~35, and a pharmaceutically acceptable carrier.

~~38~~37. ~~A method for treating a disease or disorder in a subject, which method comprises administering to the subject in need thereof a therapeutically effective amount~~ Use of a compound of any one of claims 1 to 29<sub>1</sub> or a pharmaceutically acceptable salt thereof<sub>1</sub> or ~~the~~ a crystalline form of any one of claims 30 to ~~36~~35, or a pharmaceutical composition of claim 36, in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder is selected from the group consisting of pulmonary hypertension, pulmonary arterial hypertension, pulmonary hypertension with left heart disease, pulmonary hypertension with lung disease and/or hypoxemia, pulmonary hypertension due to chronic thrombotic and/or embolic disease, and diseases associated with pulmonary hypertension including sarcoidosis, histiocytosis X, lymphangiomatosis and compression of pulmonary vessels.

~~39~~38. ~~The method use of claim 38~~37, wherein the disease or disorder is pulmonary arterial hypertension.

~~40. Use of a compound of any one of claims 1 to 29 or a pharmaceutically acceptable salt thereof or the crystalline form of any one claims 30 to 36, for treating a disease or disorder, wherein the disease or~~

disorder is selected from the group consisting of pulmonary hypertension, pulmonary arterial hypertension, pulmonary hypertension with left heart disease, ~~pulmonary hypertension with lung disease and/or hypoxemia, pulmonary hypertension due to chronic thrombotic and/or embolic disease, and diseases associated with pulmonary hypertension including sarcoidosis, histiocytosis X, lymphangiomatosis and compression of pulmonary vessels.~~

41. ~~\_\_\_\_\_ The use of claim 40, wherein the disease or disorder is pulmonary arterial hypertension.~~

4239. ~~A method for treating abnormal cell growth in a subject, which method comprising administering to the subject in need thereof a therapeutically effective amount~~Use of a compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, or the a crystalline form of any one of claims 30 to 3635, or a pharmaceutical composition of claim 36, in the manufacture of a medicament for treating abnormal cell growth.

4340. ~~The method use of claim 4239, wherein the abnormal cell growth is cancer.~~

4441. ~~The method use of claim 4340, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer and thyroid cancer.~~

45. ~~\_\_\_\_\_ Use of a compound of any one of claims 1 to 29 or a pharmaceutically acceptable salt thereof or the crystalline form of any one of claims 30 to 36, for treating abnormal cell growth.~~

4642. ~~A method for inhibiting CDK comprising contacting the CDK with~~Use of a compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, or the a crystalline form of any one of claims 30 to 3635, or a pharmaceutical composition of claim 36, in the manufacture of a medicament for inhibiting CDK.

4743. ~~A combination comprising a compound of any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, or the a crystalline form of any one of claims 30 to 3635, or a pharmaceutical composition of claim 36, and another therapeutic agent.~~